- Home
- ODD vs TLX Comparison
ODD vs TLX Comparison
Compare ODD & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODD
- TLX
- Stock Information
- Founded
- ODD 2018
- TLX 2015
- Country
- ODD Israel
- TLX Australia
- Employees
- ODD N/A
- TLX N/A
- Industry
- ODD
- TLX Biotechnology: Pharmaceutical Preparations
- Sector
- ODD
- TLX Health Care
- Exchange
- ODD Nasdaq
- TLX Nasdaq
- Market Cap
- ODD 3.8B
- TLX 3.6B
- IPO Year
- ODD 2023
- TLX N/A
- Fundamental
- Price
- ODD $45.80
- TLX $10.80
- Analyst Decision
- ODD Buy
- TLX Strong Buy
- Analyst Count
- ODD 11
- TLX 4
- Target Price
- ODD $75.36
- TLX $21.00
- AVG Volume (30 Days)
- ODD 651.0K
- TLX 118.4K
- Earning Date
- ODD 11-19-2025
- TLX 01-01-0001
- Dividend Yield
- ODD N/A
- TLX N/A
- EPS Growth
- ODD 25.95
- TLX N/A
- EPS
- ODD 1.80
- TLX 0.04
- Revenue
- ODD $751,854,000.00
- TLX $664,225,558.00
- Revenue This Year
- ODD $25.43
- TLX N/A
- Revenue Next Year
- ODD $20.18
- TLX N/A
- P/E Ratio
- ODD $25.47
- TLX $335.52
- Revenue Growth
- ODD 26.12
- TLX 55.35
- 52 Week Low
- ODD $35.30
- TLX $8.93
- 52 Week High
- ODD $79.18
- TLX $30.36
- Technical
- Relative Strength Index (RSI)
- ODD 23.41
- TLX 55.71
- Support Level
- ODD $49.17
- TLX $10.72
- Resistance Level
- ODD $52.00
- TLX $11.00
- Average True Range (ATR)
- ODD 2.33
- TLX 0.28
- MACD
- ODD -0.57
- TLX 0.10
- Stochastic Oscillator
- ODD 1.11
- TLX 73.12
About ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.